Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
With
Carelon Research
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
COPD diagnosis as defined by the study physician
Currently on one of the following maintenance therapies:
* LAMA monotherapy
* LABA monotherapy
* ICS/LABA (FDC)
Physician determination that patient is not controlled on current pharmacotherapy
Adult patient 40 years of age or older at time of study enrollment
Willingness and ability to understand and provide documented Informed Consent Form (ICF) and Health Insurance Portability and Accountability Act (HIPAA) Authorization Form prior to commencement of any study required assessments, either directly or through Legally Authorized Representative.
You may not be if
Currently on LAMA/LABA (free or FDC) or triple therapy (ICS plus LABA plus LAMA)
Contraindication to any study medications (LAMA, LABA or ICS)
Documented diagnosis of current asthma
Pregnant or nursing women
Women of childbearing potential are not restricted in this trial, however it is expected that the investigator will assess the risks and benefits of the assigned treatment as per the product label(s) and discuss this with any women of childbearing potential prior to providing the patient with the prescription for the assigned treatment.
Clareo Health | Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]
